Loading…
AMINOMIX PERIPHERAL is a brand name for Valine. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Aminomix Peripheral is indicated in adult patients whenever parenteral nutrition with amino acids, together with electrolytes and glucose is needed, when oral or enteral nutrition is impossible, insufficient, or contraindicated.
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Adult population The dose should be adjusted according to the required amino acids, glucose, electrolytes, and fluid as well as the clinical and nutritional status of the patient. The general principles and recommendations for use and dose of amino acids, glucose, and electrolytes within parenteral nutrition as well as the guidelines for fluid replacement should be followed.
Additional energy requirements should be met by adequate intravenous administration of lipid emulsions. 5 g glucose/kg bw/day).
Duration of treatment:
The duration of intravenous administration of Aminomix Peripheral depends on the patient's condition and nutritional requirement. Intravenous infusion of lipids, vitamins, additional electrolytes, and trace elements should be considered depending on the patient’s clinical condition.
Paediatric population Due to its amino acid composition Aminomix Peripheral is not suitable for the use in newborns or infants below 2 years of age. Safety and efficacy of Aminomix Peripheral in children and adolescents aged 2 to 18 years have not been established.
No study data are available. Method of administration For intravenous use by infusion via a peripheral or central vein. 18 g glucose/kg bw/h). The recommended maximum infusion time for a bag in use is 24 hours.
a) Summary of the safety profile The undesirable effects known for similar amino acid and glucose solutions might also apply to Aminomix Peripheral. Allergic reactions to any of the ingredients in Aminomix Peripheral may occur and as with all infusions in peripheral veins injection site irritation and thrombophlebitis may occur.
4 Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Individual adjustment of dose as well as regular clinical and laboratory controls are required in patients with hepatic, renal, cardiac or pulmonary disease and in patients with altered amino acid and glucose metabolism as well as lactic acidosis and increased serum osmolarity.
Depending on the clinical condition, blood levels of glucose, urea, ammonia, and electrolytes should be controlled. Patients receiving intravenous nutrition should be monitored according to the current guidelines. If the glucose clearance capacity is exceeded, hyperglycaemia can develop.
Hyperglycaemia should then be treated according to the clinical situation either by appropriate insulin administration and/or adjustment of the infusion rate. In underfed patients, initiation of intravenous nutrition can induce refeeding syndrome.
This includes fluid shifts resulting in pulmonary oedema, congestive heart failure, dysrhythmia, and decrease in serum concentrations of potassium, phosphate, magnesium, and water-soluble vitamins. These changes can occur within 24 to 48 hours.
Therefore, careful initiation of slow infusion and controls with appropriate adjustments are recommended. Given the risk of infection associated with the use of any intravenous infusion, strict aseptic precautions should be taken to avoid any contamination during catheter insertion and manipulation.
The catheter insertion site should be inspected daily for local signs of irritation and thrombophlebitis to evaluate changing the infusion site. g. nausea, vomiting, shivering, sweating, increased body temperature. With impaired renal or hepatic function urea or ammonia may be increased, respectively.
Any sign or symptom of anaphylactic reaction such as fever, shivering, rash, or dyspnoea should prompt immediate interruption of the infusion. When making additions, the final osmolarity of the mixture must be considered before administration.
, metabolic acidosis, hyperammonemia, uremia, insulin-refractory hyperglycemia, hyperglycemic hyperosmolar state, diabetic ketoacidosis), and pathologically elevated serum levels of any of the included electrolytes. - Newborns or infants below 2 years of age.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Valine in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
The mixture obtained must be administered through a central or peripheral venous line depending on its final osmolarity. If the final mixture administered is hypertonic, it may cause irritation of the vein when administered into a peripheral vein.
Contains 63 g Glucose/l. This should be taken into account in patients with diabetes mellitus. This medicinal product contains 19 mmol potassium/l. To be taken into consideration in patients with reduced kidney function or patients on a controlled potassium diet.
This medicinal product contains 25 mmol sodium/l. 79 mg phenylalanine/l and may be harmful for people with phenylketonuria. Aminomix Peripheral is a preparation of complex composition. 2).